Ublituximab Reduces Thalamic Volume Loss and New Lesion Formation in Participants of the ULTIMATE I & II Phase 3 Studies By admin / 10/11/2023
Ublituximab Is Associated with Significant Improvement in Fatigue: Results from Ultimate I and II By admin / 06/01/2023
Ublituximab, a Novel, Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Enhanced Antibody-Dependent Cellular Cytolysis (ADCC) Relative to Other Anti-CD20 mAbs By admin / 04/25/2023
Ublituximab Efficacy in Treatment-Naive Participants With Relapsing Multiple Sclerosis in the Phase 3 ULTIMATE I and II Studies By admin / 04/24/2023
Disease Outcomes With Ublituximab in Participants With Highly Active Disease: Subpopulation Analyses of the Phase 3 ULTIMATE I and II Studies in Participants With Relapsing Multiple Sclerosis By admin / 04/24/2023
Onset and Maintenance of No Evidence of Disease Activity With Ublituximab: Analyses of the Phase 3 ULTIMATE I and II Studies in Participants With Relapsing Multiple Sclerosis By admin / 02/23/2023
Early, Transient Shift in Hematologic Parameters Observed With Ublituximab in the ULTIMATE I and II Phase 3 Studies By admin / 02/23/2023
First-in-Human (FIH) Study of the Fully-Human Kappa-Lambda CD19/CD47 Bispecific Antibody TG-1801 in Patients (pts) with BCell Lymphoma By admin / 12/11/2022
Functional Systems Scores and Expanded Disability Status Scale Score Evaluations in the ULTIMATE I and II Studies of Ublituximab Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis By admin / 10/26/2022
Disability Changes in the Absence of Relapse in the Phase 3 ULTIMATE I and II Studies of Ublituximab Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis By admin / 10/26/2022
